Unity Biotechnology Management

Management Kriterienprüfungen 3/4

Unity Biotechnology CEO ist Anirvan Ghosh , ernannt in Mar 2020, hat eine Amtszeit von 4.67 Jahren. Die jährliche Gesamtvergütung beträgt $1.26M , bestehend aus 48.3% Gehalt und 51.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.44% der Aktien des Unternehmens, im Wert von $83.83K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.5 Jahre bzw. 6.3 Jahre.

Wichtige Informationen

Anirvan Ghosh

Geschäftsführender

US$1.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	48.3%
Amtszeit als Geschäftsführer	4.7yrs
Eigentum des Geschäftsführers	0.4%
Durchschnittliche Amtszeit des Managements	4.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.3yrs

Jüngste Management Updates

Recent updates

Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

Nov 05

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Anirvan Ghosh im Vergleich zu den Einnahmen von Unity Biotechnology verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$22m
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$1m	US$609k	-US$40m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$2m	US$580k	-US$44m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$59m
Mar 31 2022	n/a	n/a	-US$64m
Dec 31 2021	US$4m	US$562k	-US$61m
Sep 30 2021	n/a	n/a	-US$70m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$82m
Dec 31 2020	US$7m	US$417k	-US$94m

Vergütung im Vergleich zum Markt: AnirvanDie Gesamtvergütung ($USD1.26M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD649.07K).

Entschädigung vs. Einkommen: AnirvanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Anirvan Ghosh (60 yo)

4.7yrs

Amtszeit

US$1,260,838

Vergütung

Dr. Anirvan Ghosh, Ph D., serves as Chief Executive Officer and Director of Unity Biotechnology, Inc. since March 30, 2020. Dr. Ghosh had been Senior Vice President, Head of Research and Early Development...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anirvan Ghosh	CEO & Director	4.7yrs	US$1.26m	0.44% $ 83.8k
Nathaniel David	Co-Founder & Executive Director	13.8yrs	US$55.20k	0.35% $ 67.2k
Lynne Sullivan	CFO & Head of Corporate Development	4.3yrs	US$771.59k	0.33% $ 62.8k
Alexander Nguyen	Chief Legal Officer	3.7yrs	US$677.80k	0.024% $ 4.5k
Jan van Deursen	Founder	13.8yrs	keine Daten	keine Daten
Daohong Zhou	Founder	13.8yrs	keine Daten	keine Daten
Przemyslaw Sapieha	Chief Scientist	3.8yrs	keine Daten	keine Daten
Alicia Tozier	Chief Strategy Officer	less than a year	keine Daten	keine Daten

4.5yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: UBXDas Führungsteam des Unternehmens gilt als erfahren (4.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anirvan Ghosh	CEO & Director	4.7yrs	US$1.26m	0.44% $ 83.8k
Nathaniel David	Co-Founder & Executive Director	13yrs	US$55.20k	0.35% $ 67.2k
Camille Samuels	Independent Director	9.7yrs	US$65.70k	0.0060% $ 1.2k
Paul Berns	Lead Independent Director	6.7yrs	US$92.70k	0.0019% $ 370.7
Keith Leonard	Chairman	8.8yrs	US$85.20k	0.13% $ 24.6k
Margo Roberts	Independent Director	5.9yrs	US$59.20k	0% $ 0
Michael Samar	Independent Director	2.5yrs	US$70.20k	0% $ 0
Gilmore O'Neill	Independent Director	3.9yrs	US$60.20k	0% $ 0

6.3yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrener Vorstand: UBXDie Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).

Unity Biotechnology Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Insufficient new directors

UNITY Biotechnology Announces Board Changes

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Recent updates

Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Price target decreased by 10% to US$6.00

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

New major risk - Financial position

Price target decreased by 13% to US$6.80

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Price target increased by 12% to US$8.80

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Price target increased by 8.8% to US$7.83

Price target decreased to US$38.00

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Price target increased to US$75.17

Price target increased to US$90.00

UNITY Biotechnology falls 7% on reverse stock split

Price target increased to US$7.83

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology cuts stock sales agreement in half to $25M

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Price target increased to US$7.50

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Price target increased to US$7.50

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Chief Medical Officer notifies of intention to sell stock

A Look At Unity's UBX1325 Phase 1 Results

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

Price target increased to US$6.86

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Price target increased to US$6.20

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: US$7.51

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: US$6.47

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Unity Biotechnology Announces Executive Changes

A Look Inside Unity Bio's Transition To An Ophthalmology Company

New 90-day high: US$4.78

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - US$2.94

Price target lowered to US$5.67

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

New 90-day high - US$9.96

Price target raised to US$23.33

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

Analyse der Geschäftsführervergütung

Geschäftsführer